Skip to main content
main-content
Top

04-29-2020 | Type 2 diabetes | Podcast | Article

Is oral semaglutide a game changer or nice-to-have for type 2 diabetes?

share
SHARE
print
PRINT
insite
SEARCH

With oral semaglutide now available in the USA and Europe, what part is it likely to play in the treatment of people with type 2 diabetes in primary care?

Neil Skolnik, Professor of Family and Community Medicine at Sidney Kimmel Medical College in Philadelphia, Pennysylvania, USA, gives his view and outlines key considerations for the use of this new medication as part of a shared decision-making process with people who have type 2 diabetes.

Listen below or subscribe to this podcast on:

Apple Podcasts | Spotify | Google PodcastsStitcher | TuneIn

About the expert

Neil Skolnik

Neil Skolnik, MD, is an academic family physician who sees patients and teaches residents and medical students in the family medicine residency program at Abington Jefferson Health in Abington, Pennsylvania. Disclosures


Full biography

share
SHARE
print
PRINT

New additions to the Adis Journal Club

A selection of topical peer-reviewed articles from the Adis journals, curated by the editors.

GLP-1 receptor agonists

Browse the latest news, clinical trial updates, and expert commentary.